{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:30:52Z","timestamp":1792672252931,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.parkreldis.2008.07.004","type":"journal-article","created":{"date-parts":[[2008,9,7]],"date-time":"2008-09-07T18:45:23Z","timestamp":1220813123000},"page":"287-294","source":"Crossref","is-referenced-by-count":70,"title":["Dopamine agonists in the treatment of early Parkinson's disease: A meta-analysis"],"prefix":"10.1016","volume":"15","author":[{"given":"William L.","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Aberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig I.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2008.07.004_bib1","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMcp043908","article-title":"Diagnosis and initial management of Parkinson's disease","volume":"353","author":"Nutt","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archneur.1982.00510210015004","article-title":"Pathogenesis of Parkinson's disease","volume":"39","author":"Mann","year":"1982","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/nen.0b013e3180415e42","article-title":"The etiopathogenesis of Parkinson disease and suggestions for future research. Part I","volume":"66","author":"Litvan","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/WNL.58.1.11","article-title":"Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"58","author":"Miyasaki","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib5","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1468-1331.2006.01547.x","article-title":"Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society \u2013 European Section. Part I: early (uncomplicated) Parkinson's disease","volume":"13","author":"Horstink","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/mds.20464","article-title":"Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004","volume":"20","author":"Goetz","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib12","first-page":"421","article-title":"Bromocriptine and levodopa in early combination in Parkinson's disease: first results of the collaborative European multicentric trial","volume":"53","author":"Olsson","year":"1990","journal-title":"Adv Neurol"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000117322","article-title":"Long-term double masked trial of early treatment with L-dopa plus bromocriptine versus L-dopa alone in Parkinson's disease: interim results","volume":"30","author":"Bakheit","year":"1990","journal-title":"Eur Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.parkreldis.2008.07.004_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000116865","article-title":"Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients","volume":"32","author":"Nakanishi","year":"1992","journal-title":"Eur Neurol"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib15","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/jnnp.57.9.1034","article-title":"A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up","volume":"57","author":"Montastruc","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib16","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/jnnp.57.8.903","article-title":"The Sydney multicenter study of Parkinson's disease: a randomized, prospective five year study comparing low dose bromocriptine with low dose levodopa\u2013carbidopa","volume":"57","author":"Hely","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib17","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00002826-199508000-00006","article-title":"Pramipexole in patients with early Parkinson's disease","volume":"18","author":"Hubble","year":"1995","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1212\/WNL.49.3.724","article-title":"Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease","volume":"47","author":"Shannon","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1212\/WNL.49.2.393","article-title":"Ropinirole for the treatment of early Parkinson's disease","volume":"49","author":"Adler","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00002826-199702000-00008","article-title":"Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage","volume":"20","author":"Gim\u00e9nez-Rold\u00e1n","year":"1997","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib21","first-page":"358","article-title":"A six-month study of pergolide and levodopa in de novo Parkinson's disease patients","volume":"21","author":"Kulisevsky","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib22","first-page":"101","article-title":"A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease","volume":"21","author":"Brooks","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib23","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial","volume":"284","author":"Parkinson Study Group","year":"2000","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000008188","article-title":"Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease","volume":"44","author":"Allain","year":"2000","journal-title":"Eur Neurol"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib25","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1034\/j.1600-0404.2000.90295a.x","article-title":"Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"101","author":"Bergamasco","year":"2000","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1353-8020(00)00023-7","article-title":"Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study","volume":"7","author":"Caraceni","year":"2001","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","article-title":"Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study","volume":"54","author":"Whone","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-510X(03)00217-X","article-title":"Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease","volume":"216","author":"Wong","year":"2003","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib30","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/mds.10538","article-title":"Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor","volume":"18","author":"Navan","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00023210-200418110-00003","article-title":"The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease. Final results of a 5-year, double-blind, levodopa-controlled study","volume":"18","author":"Bracco","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib32","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archneur.61.7.1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease. A 4-year randomized controlled trial","volume":"61","author":"Parkinson Study Group","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mds.20361","article-title":"Trial of subtherapeutic pergolide in de novo Parkinson's disease","volume":"20","author":"Grosset","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mds.20724","article-title":"Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study","volume":"21","author":"Oertel","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib35","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/mds.21122","article-title":"Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN study","volume":"21","author":"Rascol","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib36","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","article-title":"Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease","volume":"68","author":"Watts","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib37","doi-asserted-by":"crossref","unstructured":"Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, et\u00a0al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database of Systematic Reviews 2008;issue 2:CD006564.","DOI":"10.1002\/14651858.CD006564.pub2"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib38","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.20201","article-title":"Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists","volume":"19","author":"Horvath","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib39","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/mds.20887","article-title":"Valvular heart disease in Parkinson's disease vs controls: an echocardiographic study","volume":"21","author":"Peralta","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib41","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/mds.21639","article-title":"Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists","volume":"22","author":"Simonis","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib42","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/01.wnl.0000215437.80053.d0","article-title":"Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Suchowersky","year":"2006","journal-title":"Neurology"},{"issue":"2, pt 1","key":"10.1016\/j.parkreldis.2008.07.004_bib43","first-page":"201","article-title":"Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease","volume":"41","author":"Kostic","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib44","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1001\/archneur.64.8.1083","article-title":"Treatment options in the modern management of Parkinson disease","volume":"64","author":"Schapira","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/01.nrl.0000215782.78763.fa","article-title":"Impact of functional age on the use of dopamine agonists in patients with Parkinson disease","volume":"12","author":"Silver","year":"2006","journal-title":"Neurologist"},{"key":"10.1016\/j.parkreldis.2008.07.004_bib46","doi-asserted-by":"crossref","unstructured":"Crosby N, Deane KHO, Clarke CE. Amantadine in Parkinson's disease. Cochrane Database of Systematic Reviews 2003;issue 1:CD003468.","DOI":"10.1002\/14651858.CD003468"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802008002162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802008002162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T17:30:54Z","timestamp":1557768654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802008002162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S1353802008002162"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2008.07.004","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}